Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1629
    +0.0018 (+0.16%)
     
  • GBP/USD

    1.2531
    +0.0007 (+0.05%)
     
  • Bitcoin GBP

    48,114.63
    -1,471.32 (-2.97%)
     
  • CMC Crypto 200

    1,253.07
    -104.94 (-7.73%)
     
  • S&P 500

    5,218.48
    +4.40 (+0.08%)
     
  • DOW

    39,479.37
    +91.61 (+0.23%)
     
  • CRUDE OIL

    78.32
    -0.94 (-1.19%)
     
  • GOLD FUTURES

    2,376.40
    +36.10 (+1.54%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

SAGE Therapeutics’ NMDA Receptor–Based Portfolio

SAGE Therapeutics’ NMDA Receptor–Based Portfolio

As discussed, SAGE Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system disorders.